Compare Cronos Group Inc (CRON) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Visa Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.20B), while Visa Inc trades at $374.9 (market cap $698.56B). The key difference: Visa Inc is far larger — about 582.1× Cronos Group Inc's market cap, and Visa Inc pays a 0.72% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Visa Inc for 115 Days on average.
| CRON | V | |
|---|---|---|
Market Cap | $1.20B | $698.56B |
Volume | 450,387 | 4,446,146 |
Sector | Health | Financials |
52-Week High | $3.55 | $384.14 |
52-Week Low | $2.30 | $295.52 |
Typical Hold Time | 22 Days | 115 Days |
Enterprise Value | $401.73M | $709.14B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 1.98% on the day, amid a bearish technical signal. The company reported mixed quarterly earnings but achieved record revenue and gross profit in Q2 2026, with net income turning positive. Recent investor day highlighted international expansion and cash flow focus. Valuation ratios show a P/E of 17.11 and P/S of 6.91, with strong net income margin of 39.08% projected for 2026.
Outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but risks include cash flow volatility and competitive pressures. Analyst consensus is mixed with 60% hold rating. The stock's near-term performance hinges on execution of expansion plans and sustained earnings momentum.
Visa (V) trades at $375.10, up 1.2% today, with a bullish technical outlook and strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $40 billion and net income of $20.06 billion, supported by high profitability margins. Recent earnings beats and a consensus analyst price target of $422.24 reflect positive sentiment, while news highlights AI integration and stablecoin partnerships as growth catalysts.
The outlook for Visa remains favorable, driven by earnings momentum and strategic initiatives in digital payments. Key risks include competitive pressures from fintech and regulatory scrutiny, but institutional ownership trends and a dominant market position underpin long-term potential. The stock offers upside based on analyst targets, though investors should monitor execution on AI and payment innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
